Glucophage and Keytruda drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Glucophage (metformin hydrochloride) and Keytruda (pembrolizumab). Common drug interactions include fluid intake reduced among females and pneumonitis among males.

The phase IV clinical study analyzes what interactions people have when they take Glucophage and Keytruda. It is created by eHealthMe based on reports of 35 people who take the same drugs from the FDA, and is updated regularly.

What is Glucophage?

Glucophage has active ingredients of metformin hydrochloride. It is often used in diabetes. eHealthMe is studying from 60,851 Glucophage users. Check the latest studies of Glucophage.

What is Keytruda?

Keytruda has active ingredients of pembrolizumab. It is often used in renal cell carcinoma. eHealthMe is studying from 57,404 Keytruda users. Check the latest studies of Keytruda.



On Jul, 17, 2026

35 people who take Glucophage and Keytruda together, and have interactions are studied.

Glucophage and Keytruda drug interactions.

What are the common drug interactions of Glucophage and Keytruda, by gender? *:

female:

  1. Fluid intake reduced
  2. Hyperglycaemia (high blood sugar)
  3. Hyperosmolar state (life-threatening emergency manifested by marked elevation of blood glucose)
  4. Hypersomnia (excessive daytime sleepiness (eds))
  5. Hypoglycaemia (deficiency of glucose in the bloodstream)
  6. Hypokalaemia (low potassium)
  7. Hyponatraemia (abnormally low level of sodium in the blood; associated with dehydration)
  8. Lymphadenopathy (disease or enlargement of lymph nodes)
  9. Mass
  10. Mental status changes (general changes in brain function, such as confusion, amnesia (memory loss), loss of alertness, loss of orientation)

male:

  1. Pneumonitis (inflammation of the walls of the alveoli in the lungs)
  2. Fatigue (feeling of tiredness)
  3. Pyrexia (fever)
  4. Vomiting
  5. Weight decreased
  6. Autoimmune myocarditis (inflammation of the heart muscle by immune system disorder)
  7. Confusional state
  8. Death
  9. Malignant neoplasm progression (cancer tumour came back)
  10. Myocardial ischaemia (the blood flow through one or more of the blood vessels that lead to heart (coronary arteries) is decreased)

What are the common drug interactions of Glucophage and Keytruda, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

  1. Blood urea increased
  2. Chills (felling of cold)
  3. Cough
  4. Device related infection
  5. Diabetes mellitus inadequate control
  6. Discomfort
  7. Drug hypersensitivity
  8. Dry mouth
  9. Dysuria (painful or difficult urination)
  10. Fall

50-59:

  1. Pneumonitis (inflammation of the walls of the alveoli in the lungs)
  2. Fatigue (feeling of tiredness)
  3. Pain
  4. Pyrexia (fever)
  5. Red blood cell count decreased
  6. Vomiting
  7. Blood albumin decreased
  8. Blood creatinine increased
  9. Blood glucose increased
  10. Blood urea increased

60+:

  1. Pneumonia
  2. Pneumonitis (inflammation of the walls of the alveoli in the lungs)
  3. Confusional state
  4. Death
  5. Myocardial ischaemia (the blood flow through one or more of the blood vessels that lead to heart (coronary arteries) is decreased)
  6. Obstruction gastric (obstruction in stomach)
  7. Adrenal insufficiency (a condition in which the adrenal glands do not produce adequate amounts of steroids)
  8. Angioedema (rapid swelling of the dermis)
  9. Aortic arteriosclerosis (hardening of the aortic arteries)
  10. Aortic stenosis (obstruction to the outflow of blood from the left ventricle into the aorta)

What are the existing conditions these people have? *

  1. Lung Cancer - Non-Small Cell (lung cancer): 9 people, 25.71%
  2. White Blood Cells Urine Positive: 6 people, 17.14%
  3. Urination - Painful: 6 people, 17.14%
  4. Stress And Anxiety: 6 people, 17.14%
  5. Ovarian Cancer (cancer of ovary): 6 people, 17.14%
  6. Malignant Melanoma (skin cancer rises from melancytes): 4 people, 11.43%
  7. Pulmonary Embolism (blockage of the main artery of the lung): 2 people, 5.71%
  8. Peripheral T-Cell Lymphoma Unspecified (peripheral t-cell cancer unspecified): 2 people, 5.71%
  9. Lung Adenocarcinoma (a form of non-small cell lung cancer): 2 people, 5.71%
  10. Heart Disease: 2 people, 5.71%

* Approximation only. Some reports may have incomplete information.

Do you take Glucophage and Keytruda?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously



Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Glucophage and Keytruda:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Glucophage:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Keytruda:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Glucophage and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Keytruda and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Related publications that referenced our studies


How the study uses the data?

The study uses data from the FDA. It is based on metformin hydrochloride and pembrolizumab (the active ingredients of Glucophage and Keytruda, respectively), and Glucophage and Keytruda (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: